NasdaqGM:RYTMBiotechs
Rhythm Pharmaceuticals (RYTM) Posts Q4 Revenue Gain That Challenges Bearish Cash Burn Narrative
Rhythm Pharmaceuticals (RYTM) has wrapped up FY 2025 with Q4 revenue of US$57.3 million and a basic EPS loss of US$0.73, while trailing 12 month figures show total revenue of US$189.8 million and a basic EPS loss of US$3.11. Over recent quarters, the company has seen revenue move from US$41.8 million in Q4 2024 to US$57.3 million in Q4 2025, with basic EPS losses ranging between US$0.72 and US$0.82 per quarter. This sets up a story where revenue is building but margins remain under...